{"id":"NCT03172780","sponsor":"Mylan Pharmaceuticals Private Limited","briefTitle":"A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee\"","officialTitle":"A Randomized, Double Blind, Three-arm, Parallel, Placebocontrolled, Clinical Study to Evaluate the Bioequivalence Using Clinical Endpoint of Diclofenac Sodium Gel, 1% (Mylan Inc.) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc.) in Patients With Osteoarthritis (OA) of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-24","primaryCompletion":"2017-12-05","completion":"2017-12-05","firstPosted":"2017-06-01","resultsPosted":"2021-04-20","lastUpdate":"2022-03-03"},"enrollment":1220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee"],"interventions":[{"type":"DRUG","name":"Diclofenac sodium gel 1%","otherNames":[]},{"type":"DRUG","name":"Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%","otherNames":[]},{"type":"DRUG","name":"Placebo gel","otherNames":[]}],"arms":[{"label":"Diclofenac Sodium Gel","type":"EXPERIMENTAL"},{"label":"Voltaren® Gel","type":"ACTIVE_COMPARATOR"},{"label":"Placebo gel","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, double-blind, three-arm, placebo controlled, bioequivalence study with clinical endpoint has been designed to establish clinical equivalence and safety of Mylan's diclofenac gel in the symptomatic treatment of osteoarthritis of knee compared to Voltaren® gel and to establish superiority in efficacy of both compared to a placebo (vehicle) gel.\n\nMale or non-pregnant female aged ≥ 35 years with a clinical diagnosis of osteoarthritis of the knee according to the American College of Rheumatology (ACR) criteria\n\nTotal study duration for the clinical part will be around 56 days that includes screening period of 28 days and treatment period of 4 weeks.","primaryOutcome":{"measure":"Mean Change in the Total WOMAC Pain Subscale Score","timeFrame":"From baseline to week 4","effectByArm":[{"arm":"Diclofenac Sodium Gel","deltaMin":-4.3,"sd":2.64},{"arm":"Voltaren® Gel","deltaMin":-4.6,"sd":2.64}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":32,"countries":["India"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":398},"commonTop":["Headache","Pyrexia","Eosinophilia"]}}